Abstract:Background: Pulmonary arterial hypertension (PAH) is a rare but severe and life-threatening condition that primarily affects the pulmonary blood vessels and the right ventricle of the heart. The limited availability of human tissue for research ~most of which represents only end-stage disease~ has led to a reliance on preclinical animal models. However, these models often fail to capture the heterogeneity and complexity of the human condition. Analyzing the molecular signatures in patient plasma provides a unique opportunity to gain insights into PAH pathobiology, explore disease heterogeneity absent in animal models, and identify potential therapeutic targets. Objective: This study aims to characterize the circulating peptides, metabolites, and lipids most relevant to PAH by leveraging unbiased mass spectrometry and advanced computational tools. Building on prior research that identified individual circulating factors, this work seeks to integrate these molecular layers to better understand their interactions and collective contribution to PAH pathobiology. Methods: Peripheral blood samples were collected from 402 patients with PAH and 76 healthy individuals. Various types of molecules in the blood ~ peptides, metabolites, and lipids ~ were measured. Statistical and machine learning methods were used to identify differences between PAH patients and healthy individuals, and further to understand how these molecules might interact with each other. A survival model was also trained to examine the association between the blood molecular signature and patient outcomes. Results: Differential abundance analysis revealed 832 peptides (from 291 proteins), 45 metabolites, and 222 lipids significantly altered in PAH compared to controls. Machine learning-based feature selection identified 11 key molecules, including 2~Hydroxyglutarate, that together achieved a classification accuracy of 98.6% for PAH in a multivariate model tested on a withheld cohort. Latent network discovery uncovered 7 distinct networks, highlighting interacting molecules from pathways ~such as hypoxia, glycolysis, fatty acid metabolism, and complement activation~ that we and others have previously linked to vascular lesions in PAH patients. A survival model incorporating 155 molecular features predicted outcomes in PAH patients with a c-index of 0.762, independent of traditional clinical parameters. This model stratified patients into risk categories consistent with established markers of cardiac function, exercise tolerance, and the REVEAL 2.0 risk score. Conclusion: This study underscores the utility of integrated omics in unraveling PAH pathobiology in human subjects. Our findings highlight the central role of hypoxia signaling pathways interacting with disrupted fatty acid metabolism, complement activation, inflammation, and mitochondrial dysfunction. These interactions, revealed through latent network analysis, emphasize the metabolic and immune dysregulation underlying PAH. Furthermore, many of the molecules identified in the circulation were consistent with pathways enriched in pulmonary vascular lesions, reinforcing their biological relevance. Circulating plasma molecules from these networks demonstrated strong prognostic capabilities, comparable to current clinical risk scores, offering insights into disease progression and potential for future clinical application.

Mechanistic Investigation of Calcium Channel Regulation-Associated Genes in Pulmonary Arterial Hypertension and Signatures for Diagnosis

Epigenetic Regulation of Pulmonary Arterial Hypertension

Lasso Algorithm and Support Vector Machine Strategy to Screen Pulmonary Arterial Hypertension Gene Diagnostic Markers

Proteomic Analysis of the Serum in Patients with Idiopathic Pulmonary Arterial Hypertension

Identification of metabolic biomarkers in idiopathic pulmonary arterial hypertension using targeted metabolomics and bioinformatics analysis

Integrated Bioinformatics Analysis Reveals Marker Genes and Potential Therapeutic Targets for Pulmonary Arterial Hypertension

Integrated bioinformatics analysis reveals marker genes and immune infiltration for pulmonary arterial hypertension

Integrated Bioinformatics Analysis and Experimental Animal Models Identify a Robust Biomarker and Its Correlation with the Immune Microenvironment in Pulmonary Arterial Hypertension

Integrated Weighted Gene Co-Expression Network Analysis Uncovers STAT1(signal Transducer and Activator of Transcription 1) and IFI44L (Interferon-Induced Protein 44-Like) As Key Genes in Pulmonary Arterial Hypertension

A comprehensive analysis of genes associated with hypoxia and cuproptosis in pulmonary arterial hypertension using machine learning methods and immune infiltration analysis: AHR is a key gene in the cuproptosis process

Molecular Characterization and Elucidation of Pathways to Identify Novel Therapeutic Targets in Pulmonary Arterial Hypertension

Identification of candidate biomarkers and molecular networks associated with Pulmonary Arterial Hypertension using machine learning and plasma multi-Omics analysis

Identification of MACC1 as a potential biomarker for pulmonary arterial hypertension based on bioinformatics and machine learning

Protein Biomarkers And Risk Scores In Pulmonary Arterial Hypertension Associated With Ventricular Septal Defect: Integration Of Multi-Omics And Validation

Comprehensive identification of signaling pathways for idiopathic pulmonary arterial hypertension

Exploring IRGs as a Biomarker of Pulmonary Hypertension Using Multiple Machine Learning Algorithms

Identification of Differentially Expressed Genes Associated with Idiopathic Pulmonary Arterial Hypertension by Integrated Bioinformatics Approaches.

Comparative Transcriptional Analysis of Pulmonary Arterial Hypertension Associated with Three Different Diseases.

Identification of fatty acid metabolism signature genes in patients with pulmonary arterial hypertension using WGCNA and machine learning

Profiling and Molecular Mechanism Analysis of Long Non-Coding RNAs and mRNAs in Pulmonary Arterial Hypertension Rat Models

Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility